Background: clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited.
Introduction
Psoriasis (PsO) is a chronic inflammatory skin disease that affects 1-3% of the worldwide population. [1] Henseler and Christophers described two clinical presentations of psoriasis, type I and II, distinguished by a bimodal age at onset. Type 1 begins on or before age of 40 years; type II begins after the age of 40 years. [2] According with different population-based studies, 3.2-13% of patients experience psoriasis first in their lives over 60 years old, and the proportion might increase in aging society. [3] [4] [5] Moreover, it is well known that PsO is associated with several comorbidities such as psoriatic arthritis (PsA), metabolic syndrome and cardiovascular diseases. [6, 7] As the number of individuals older than 65 years continues to rise, psoriasis and chronic diseases associated with psoriasis will likely increase in the geriatric population.
Therefore, dermatologists will face a significant challenge in psoriasis management in older adults. However, clinical studies of psoriasis in this specific age group have been rarely conducted. In fact, the elderly are more likely to have arthritis, bone and joint disorders, cancers, and other chronic disorders associated with a dramatic impact in quality of life.
Taking into consideration the comorbidities of a geriatric population of psoriatic patients, systemic therapies are often contraindicated. However, few studies and limited clinical trials evaluated the safety of conventional and biologic therapies in the treatment of elderly psoriatic patients especially in the long term. [8] [9] [10] [11] . Among biologics, Infliximab (Remicade®) is a chimeric human-murine IgG1k monoclonal antibody, which binds with high affinity, avidity and specificity to TNFα approved by the EMA and FDA for the treatment of both PsO and PsA [12] .This study aims to report our long-term experience on safety, efficacy and tolerance of infliximab in elderly patients under treatment with infliximab.
Material and Methods
A retrospective review of the clinic database at the Department of Dermatology of the University of Rome Tor Vergata using the term "infliximab" was undertaken. Using this database-generated list, all charts were reviewed identifying psoriatic patients older than 65, treated in the day-care unit from 2002 to 2014.
The baseline characteristics of age, sex, psoriasis phenotype, onset of the disease, comorbidities, previous systemic treatments for psoriasis and any concurrent medications were obtained.
According with the European and Italian guidelines all treated patients were unresponsive or contraindicated to at least two systemic conventional therapies. [13] Patients with infectious disease, active or latent tuberculosis (TBC), HIV, neoplastic disease (in the previous 5 years), severe heart failure, or demyelinating disorders were excluded.
Infliximab was administrated intravenously at week 0, 2, 6 and then every 8 weeks. Clinical evaluation was assessed at each infusion using the validated psoriasis area and severity index (PASI).
At each infusion, physical examination, standard laboratory tests as well as measure of vital signs were assessed. The occurrence of adverse events (AEs) was also investigated and they were classified in mild, moderate and severe.
The safety analyses were performed in all subjects who received at least one dose of infliximab. Laboratory data were recorded by visit descriptively and normal ranges pre-treatment versus post-treatment was provided.
Statistical analysis: Data from the clinical laboratory analyses were entered into a
Windows-based database (Microsoft Excel 2007); all statistical analyses were expressed as means ± standard deviation (SD). The significance of difference in the mean values obtained at T0, W12, 52, 104, and of treatment was assessed with an unpaired Student's t test (statistical significance set at p ≤ 0.05).
Results
A total of 151 charts of patients treated with infliximab during the study period were analyzed.
Twenty-seven/151 patients met the study criteria for inclusion. The range of the age was between 65-85 years old, average age 72 ± 5.2, female to male ratio was 1:2 and the mean age of onset was 43 years old ±17. Fourteen patients suffered from plaque type psoriasis and 13 from psoriatic arthritis. Comorbidities included obesity, hypertension, gastrointestinal and cardiovascular diseases, diabetes mellitus, osteoporosis, hypercholesterolemia and thyroid dysfunction are reported in detailed in table 1. Three patients were also positive to TB Gold Quantiferon at the baseline and prophylaxis was prescribed according with the guidelines. [14] The average of treatment duration was 39 months ± 27 (range 1-100 months), with an average At week 12 a reduction in PASI score was observed in 80% of the patients: 4 patients achieved (PASI50), 3 patients between PASI75, 5 patients between PASI90 and 13 patients PASI 100 (Table 2) . At week 12, 52, 104, and 208 the mean PASI was 2, 2.3, 1.9 and 1.8 respectively ( Figure 1 ). The reduction in the mean PASI score was significant (p<0.001) from week 12 and maintained at week 208. Only 2 patients had a worsening of the disease.
Fifteen/27 discontinued the treatment for the following reasons: 6 patients for lack of efficacy (between week 38 and week 78), 2 continued the infusions in a different hospital, and 3 for adverse events. Adverse events are described in table 3 and those leading to discontinuation included TBC reactivation (n=1 at week 86), surgical operation (n=1 at week 54) and spondylodiscitis (n=1 at week 30).
Infusions reactions were mild and led to treatment discontinuation in 2 patients at week 14 and week 46 (orticarioid reaction and uncontrolled arterial hypertension).
Twelve patients are currently under treatment (>100 months therapies) showing efficacy and maintenance of PASI75 in the long-term (p<0.001) associated with a safety profile.
Discussion
In this article we report evidence of long-term safety and efficacy of infliximab in elderly psoriatic patients. To our knowledge, few clinical researches were focused in studying geriatric psoriatic patients under treatment with biologics in particular with infliximab. In our study we reported in 27 elderly patients under treatment with infliximab a rapid PASI score reduction and these results were maintained in the long-term in 12 patients without discontinuation. Infusion reactions were mild. Several studies have shown the efficacy and safety profile of infliximab in plaque-type psoriasis, PsA, pustular and erytrodermic psoriasis as monotherapy or in combination with Methotrexate in children and adults. [15] [16] [17] In our experience, infliximab was safe in the long-term as monotherapy or in combination with
Methotrexate. The safety profile should be a primary need especially in elderly patients in whom the comorbidities should be taken into consideration when a treatment is proposed, for the higher risk of side effects and drug interactions. The frequent association with other major comorbidities requires efficacious treatment options that can be safely administered on a long-term period.
Moreover, adherence to therapies is a primary determinant of treatment success and physicians, and nurses have a key role to improve patient medication adherence in geriatric patients that need short hospitalization for infliximab infusions. A survey that asked which route of administration for anti-TNF therapy was preferred by patients with rheumatoid arthritis indicated a preference for IV administration (that is, with infliximab) over a subcutanoeus regimen [18] . In this survey, factors for this preference included patients' general dislike of subcutanoeus injections, pain and irritation at the injection site, more frequent administration of the subcutanoeus -administered drug , difficulty in handling secure medication containers, and the clinical assistance attendant on IV administration. [18] In fact, in our experience IV dosing allows continuous dosage adjustments to be made, affording flexibility in matching patient needs at any given time during the infusion, helping to optimize overall treatment outcomes, appropriate monitoring and early diagnosis of comorbidities (i.e. blood pressure is continuously monitored during the infusions, blood exams are performed at each infusion). The latter could be related to the safety profile observed in our elderly population.
Even if in a small cohort of patients, our data suggested that infliximab is well tolerated, safe, and effective in the long term in treating elderly patients affected by psoriasis or psoriatic arthritis despite common comorbidities occurring in an over-65 years old population. The IV therapy was also associated with a high compliant profile and the hospitalization and the monitoring of vital signs as well as the clinical visit assessed at any infusion can lead to early diagnosis of comorbidities.
Expert opinion
In elderly patients the chronic nature of the disease and the association with other major comorbidities requires efficacious treatment options that can be safely administered on a continuous long term basis. In contrast to subcutaneous drugs, the IV therapy allows a constant and continuous evaluation of patients' comorbidities and possible adverse events by radiological exams, blood tests, and measurement of vital parameters. The latter were taken at each infusion leading to early recognition of undiagnosed cardiovascular diseases (i.e. hypertension), pneumological conditions (i.e. COPD), infections or even cancers. However, since elderly minorities have low clinical trial participation in psoriatic population, our limited experience suggests that infliximab is safe, effective and associated with a high compliance in the long term.
Finally, effectiveness and safety outcomes appear to be comparable between intravenous and subcutaneous anti-TNF-alpha agents in elderly patients with PsO and PsA.
